Omar Mian

Has grant

Associate Professor

Fred Hutch Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Omar Mian is an Assistant Professor at the Cleveland Clinic Foundation in the United States. His research areas include radiation therapy for bladder cancer, small-cell carcinoma of the genitourinary tract, and the impact of endocrine signaling on cancer. He has contributed to several articles focusing on patient-specific adaptive planning for radiation therapy, novel therapeutic approaches in neuroendocrine tumors, and advancements in bladder-sparing strategies for muscle-invasive bladder cancer.

Recent Grants

Grant: Close

Dissecting the epigenetic drivers of neuroendocrine transdifferentiation

Open Date: 2020-09-01

Close Date: 2024-08-31

Grant: Close

Targeting HSD3B1-Associated Extragonadal Androgen Biosynthesis to Sensitize Lethal Prostate Cancer

Open Date: 2016-10-01

Close Date: 2017-09-01

Articles (7)

Background Whole bladder irradiation is an organ preservation treatment approach for muscle‐invasive bladder cancer (MIBC). Conventional planning margins, typically 15–20 mm, increase normal tissue toxicity and limit possible dose escalation. Purpose The study aimed to develop a patient‐specific adaptive margin recipe for whole bladder irradiation to minimize the planning target volume (PTV) while preserving adequate dose coverage. Methods Sixteen patients who received whole‐bladder irradiation were retrospectively selected for this study. We proposed a patient‐specific anisotropic adaptive margin recipe, derived from the first five fractions of kV‐CBCTs, to account for inter‐fractional bladder changes. This recipe was validated using kV‐CBCTs from fractions six to ten and the final five fractions. The goal was to achieve a residual volume, defined as the percentage of daily bladder volume (V daily ) outside the PTV, of less than 5%. Adaptive and conventional plans were created using proposed and conventional margins, respectively. A dosimetric comparison of targets and organs‐at‐risk (OARs) was performed between the two approaches. Results (V daily ) decreased throughout the treatment course. The most notable inter‐fractional bladder variations were in the superior and anterior directions. The patient‐specific anisotropic adaptive margins, averaging 6 mm (± 2.9 mm), achieved a residual volume of less than 5%. Compared to conventional planning, the adaptive approach reduced PTV volume by an average of 135.3 cc (± 46.6 cc). A significant correlation ( p < 0.05) was identified between residual volume and adaptive margins in the anterior, superior, left, and right directions. Using the proposed adaptive margins, the median residual volume was 0.71% (interquartile range 0.09%−3.55%), and the median (V daily ) receiving the prescribed dose was 99.1% (interquartile range 95.3%−99.9%). Adaptive plans demonstrated superior OAR sparing compared to conventional plans. Conclusions The proposed patient‐specific adaptive margin recipe for whole bladder irradiation resulted in margins smaller than conventional ones, optimized normal tissue sparing, and maintained adequate PTV coverage.

Year:

2025

Year:

2025

Small-cell carcinomas (SCCs) of the genitourinary (GU) tract are rare malignancies with high metastatic potential. The most common primary sites are the bladder and prostate, but case reports of primary SCC of the kidney, ureter, and urethra also exist. The majority of patients present with gross hematuria, irritative or obstructive urinary symptoms, and symptoms of locoregionally advanced or metastatic disease at initial presentation. SCC of the bladder presents with nodal or metastatic involvement in the majority of cases and requires the use of platinum-based chemotherapy in combination with surgery and/or radiation. SCC of the prostate is most commonly seen in the metastatic castrate-resistant setting, and aggressive variant disease presents with a greater propensity for visceral metastases, osteolytic lesions, and relatively low serum prostate-specific antigen for volume of disease burden. Multiple retrospective and prospective randomized studies support the use of a multimodal approach combining platinum-based systemic therapy regimens with radiation and/or surgery for localized disease. This evidence-based strategy is reflected in multiple consensus guidelines. Emerging data suggest that small-cell bladder and prostate cancers transdifferentiate from a common progenitor of conventional urothelial bladder carcinoma and prostatic acinar adenocarcinoma, respectively. Areas of active basic research include efforts to identify the key genetic and epigenetic drivers involved in the emergence of small cell cancers to exploit them for novel therapies. Here, we review these efforts, discuss diagnosis and currently supported management strategies, and summarize ongoing clinical trials evaluating novel therapies to treat this rare, aggressive GU cancer.

Year:

2024

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Collaborators (1)

Melissa Huynh

Assistant Professor

Western University

CANADA
View details